Clinical Scorecard: Cell and Gene Roundup: CAR T Breaks New Ground
At a Glance
| Category | Detail |
|---|---|
| Condition | Acute Myeloid Leukemia (AML) |
| Key Mechanisms | CAR T-cell therapy targeting CD64 protein on AML cells |
| Target Population | Adults with relapsed or refractory AML |
| Care Setting | Clinical trial at UCHealth University of Colorado Hospital |
Key Highlights
- First U.S.-cleared CAR T program for adults with relapsed/refractory AML
- Targets CD64, a protein on aggressive AML cells
- Phase 1 trial to assess safety, tolerability, and optimal dose
- Potential expansion to pediatric trials in 2026
- Direct pipeline from lab to bedside for patients with limited options
Guideline-Based Recommendations
Diagnosis
- Assess for relapsed or refractory AML
Management
- Initiate CAR T-cell therapy targeting CD64
Monitoring & Follow-up
- Evaluate safety and tolerability during clinical trials
Risks
- Potential for off-target effects and immune response
Patient & Prescribing Data
Adults with limited treatment options for relapsed or refractory AML
CAR T therapy shows promise in targeting persistent AML cells
Clinical Best Practices
- Conduct thorough patient selection for CAR T therapy
- Monitor for adverse effects during treatment
- Consider combination therapies to enhance efficacy
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
